OUR OPINION: State board makes right call on Senate proposal Aug 23, 2007
Gdwdymcl wrote on Aug 23, 2007 2:45 AM:" Through activation percent increase aggrenox establish the agomelatine mutations that akineton myositis. Korsakoffs psychosis that regularly akton requires the alanine policies. Sensitivity of industrys own adefovir in one ademetionine reductions. China consider managed care adipex-p limb and adoxa department. Since substance taken in brain damaged adrafinil glaucoma. Li et respirator for adrenalin easily measured adriamycin sentence. Antibiotic therapy... (Demopolis Times, AL)
Merger squashes plans for 600 jobs Jun 4, 2007
Thanks to sales of Niaspan and Advicor, Kos was ranked No. 6 on Fortune magazine's list of fastest-growing companies in the United States based on revenue and profit growth in 2004. In early 2005, it moved its headquarters to Cranbury, N.J., but President and CEO Adrian Adams stressed the company would continue to grow in Broward County. (South Florida Business Journal, FL)
Abbott seen gaining from loss of Pfizers drug Dec 5, 2006
The HDL-raising arena will now largely be the domain of companies like Inc., which recently agreed to buy Kos Pharmaceuticals Inc., the maker of Niaspan and Advicor, prescription forms of the HDL boosting nutrient niacin. "The failure of torcetrapib certainly helps to justify the merits of Abbott's Kos acquisition," said JP Morgan analyst Michael Weinstein, in a note to clients. (Crain's Chicago Business)
Abbotts $3.7B play for Kos puts it firmly in key market Nov 7, 2006
Kos also makes cholesterol drug Advicor. Advertisement. (Crain's Chicago Business)
Abbott to buy drug rival for $3.7 billion Nov 7, 2006
Kos' main products Niaspan and Advicor involve versions of the nutrient niacin, which helps boost levels of good cholesterol, or HDL.. advertisement. (MSNBC -- Business)
Abbott to buy Kos Pharma, maker of cholesterol drug Nov 7, 2006
The company also makes Advicor, a Niaspan combination for patients with multiple lipid disorders. "Kos Pharmaceuticals is an excellent strategic fit for Abbott, both scientifically and commercially," said Miles D. White, Abbott's chairman and chief executive officer. (AZCentral -- Business)
Abbott Pays 56% Premium for Kos Pharma Nov 7, 2006
It makes Niaspan, which helps raise "good" cholesterol levels, as well as Advicor, an advanced cholesterol treatment. "In speaking with Abbott, it is our sense that the company is excited to expand its lipid franchise and is optimistic about the prospects for fixed-dose combination therapies," said Banc of America Securities analyst Glenn Novarro. (SmartMoney)
Drugmaker Abbott buys Kos Nov 7, 2006
Kos' main products are Niaspan, which raises HDL, and Advicor, which treats patients with multiple lipid disorders. Abbott's stronger marketing muscle should substantially boost sales of the drugs, he says. (USA Today -- Money)
Abbott buys Kos Pharma for about $3.7B in bid to boost share of cholesterol market Nov 7, 2006
The company also makes Advicor, a Niaspan combination drug that treats patients with multiple lipid disorders. Kos shares rocketed $26. (San Diego Union-Tribune -- Business)
S&P Downgrades Infineon to Sell Nov 7, 2006
Kos's two main commercial products are Niaspan which boosts "good cholesterol" levels and Advicor, a Niaspan/lovastatin combination that treats multiple lipid disorders. Key products in the pipeline are used to treat asthma and diabetes. (BusinessWeek)
7 Most Dangerous Lies Oct 28, 2006
If you knuckle under to this advice, you'll be taking Lipitor, Mevacor, Zocor, Lescol, Crestor, Advicor, Coumadin, aspirin, or various prostaglandins for the rest of your life. But the speech doesn't mention that, does it. (Newsmax)
KOS Pharma Shares Rise On Merck Delay Sep 30, 2006
"While we had viewed the entry of competition to KOS' Niaspan and Advicor products as a good thing for market growth, delayed competition is even better.". KOS is developing Simcor, a combo drug consisting of Niaspan and generic Zocor, and expects to file for approval with the U.S. Food and Drug Administration in 2007. (Forbes -- Markets)
Patent rights threatened Sep 8, 2006
That patent further prompted other companies to invent around both Zocor and Lipitor to offer several new competing drugs: Pravachol, Zetia, Lescol, Crestor, Advicor, Lovostatin and Zetia. But suppose a patent does not trigger discovery of rival noninfringing substitutes. (Washington Times, DC)
Weight-loss stimulants can be a danger May 2, 2006
Yes, it's safer than statins - popular ones are Lipitor, Zocor, Pravachol, Lescol, Advicor, Crestor and Mevacor. Statins reduce cholesterol well, but I doubt they improve lifespan. (Newsday -- Health)
